GleamWall
中文EN

AURX Nuo Therapeutics, Inc.

Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1091596 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY123.7%
TTM net income YoY2.0%
TTM EPS YoY—
Revenue 3-yr CAGR308.7%
Net income 3-yr CAGR—

Margins

Gross margin70.4%
Operating margin-98.3%
Net margin-93.1%
FCF margin-44.6%
EBITDA margin-95.5%

Returns

ROE-1,032.5%
ROA-133.3%
ROIC (approx.)—
Asset turnover1.43x

Leverage & solvency

Liabilities / assets121.8%
Debt / equity—
Current ratio1.16x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.38x
Accruals ratio-82.1%
Payout ratio—
Capex / revenue8.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.87M$1.77M$1.30M$1.10M$1.03M$700,202$484,381$394,872
Cost of revenue$673,334$598,959$452,388$408,461$406,721$159,350$121,021$86,412
Gross profit$1.19M$1.17M$849,727$688,369$625,375$540,852$363,360$308,460
SG&A expense$1.57M$1.34M$1.30M$1.27M$1.17M$1.19M$1.11M$937,694
Operating income-$374,432-$166,552-$446,466-$579,338-$540,142-$652,022-$745,147-$629,234
Net income-$424,928-$277,601-$618,466-$578,480-$537,919-$649,689-$746,128-$496,666
EBITDA-$373,820-$140,354-$424,210-$555,426-$516,994-$628,966-$729,800-$617,718
EPS (basic)-0.01-0.01-0.01—-0.01-0.01-0.02—
EPS (diluted)————————
Balance sheet
Cash & equivalents$80,941$449,325$263,827$548,946$514,797$316,354$55,655$283,714
Receivables$1.41M$1.17M$873,669$561,667$652,252$320,440$276,532$248,205
Inventory$330,134$269,518$248,537$213,761$201,627$165,816$99,173$150,442
Current assets$1.98M$1.99M$1.52M$1.38M$1.46M$853,280$601,506$841,546
PP&E, net$704,903$571,735$344,906$366,315$347,022$370,170$391,559$177,022
Total assets$2.73M$2.63M$1.95M$1.85M$1.93M$1.36M$1.15M$1.19M
Current liabilities$2.45M$1.55M$1.37M$1.31M$1.26M$998,955$1.28M$578,451
Total liabilities$4.58M$4.16M$3.33M$2.80M$2.35M$2.18M$1.36M$675,796
Shareholders' equity-$1.85M-$1.54M-$1.38M-$956,559-$419,606-$824,561-$213,073$513,712
Shares outstanding48.57M48.42M48.29M48.18M47.88M46.83M46.82M46.82M
Cash flow statement
Operating cash flow-$194,604-$236,475-$784,272-$422,646-$706,516$262,366$1,825-$490,539
Capital expenditure$173,780$253,027$847$43,205$0$1,667$229,884$0
Free cash flow-$368,384-$489,502-$785,119-$465,851-$706,516$260,699-$228,059-$490,539
Investing cash flow-$173,780-$253,027-$847-$43,205$0-$1,667-$229,884$0
Financing cash flow$0$675,000$500,000$500,000$904,959$0$0$90,417
Depreciation & amortization$612$26,198$22,256$23,912$23,148$23,056$15,347$11,516
Stock-based compensation$89,238$41,490$23,527$23,527$19,915$23,201$19,343$29,574

Free plan shows the latest 8 periods; Pro shows all 65 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.